Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Receivables (2016 - 2025)

Dexcom (DXCM) has disclosed Receivables for 16 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 20.91% to $1.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 billion, a 20.91% increase, with the full-year FY2025 number at $1.2 billion, up 20.91% from a year prior.
  • Receivables was $1.2 billion for Q4 2025 at Dexcom, up from $1.1 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.4 billion in Q2 2025 to a low of $455.6 million in Q1 2021.
  • A 5-year average of $825.9 million and a median of $777.2 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 62.86% in 2021, then grew 4.91% in 2024.
  • Dexcom's Receivables stood at $523.9 million in 2021, then soared by 37.87% to $722.3 million in 2022, then skyrocketed by 35.94% to $981.9 million in 2023, then increased by 4.91% to $1.0 billion in 2024, then increased by 20.91% to $1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Receivables are $1.2 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.4 billion (Q2 2025).